CIDP enrollment is hard because the diagnosis is hard. Our medical-operations team pre-qualifies complex neuropathy patients before site referral.

Leapcure runs recruitment for rare, immune-mediated, neuromuscular conditions. We rescue trials that are behind, and we pre-qualify patients before your sites ever see them.

Talk to our CIDP teamSee how it works →
8 of 10
Final enrollments delivered
in an adjacent rare neuromuscular rescue (Myasthenia Gravis, Phase 2)
530+
Patients pre-screened
by our team in that adjacent rare-disease program
2 days
To mobilize
existing rare-disease advocacy and patient networks
~70%
Average enrollment contribution
across Phase 2 rare autoimmune and neuromuscular studies

Understanding CIDP as a Clinical Trial Indication

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, acquired, immune-mediated disorder in which the immune system attacks the myelin sheath of the peripheral nerves, producing progressive or relapsing weakness and sensory loss. It belongs to the family of rare, immune-mediated, demyelinating neuro-immunology conditions alongside Myasthenia Gravis and NMOSD, and it carries the same recruitment profile: a small, dispersed population, a hard and often delayed diagnosis, and patients who are reached only through the specialists and communities they already trust. US prevalence is about 8.9 per 100,000 (Frontiers in Neurology, 2025), so reaching enough eligible patients means reaching them across many regions at once.

CIDP is genuinely hard to enroll because it is genuinely hard to diagnose. Confirmation depends on nerve conduction studies and EMG, and patients are frequently misdiagnosed before they ever reach a specialist. Many are managed by community neurologists rather than academic centers, eligibility is complex and heterogeneous, treatment histories (IVIG, corticosteroids, plasma exchange) have to be reconciled, and long, event-driven trials carry real dropout risk. Generic, ad-volume recruitment surfaces patients who fail screening and rarely reaches the right communities at all.

Leapcure recruits for exactly this kind of trial. We reach hard-to-find patients through specialist and physician networks (the community neurologists who actually see CIDP), bring volume through precision digital, and lean on a Patient Success Team that works complex eligibility detail before site referral and supports patients and their families through it. CIDP is won on specialist reach, pre-screening, and trust, not ad volume. We show our proof as what it is: in an adjacent Phase 2 rare neuromuscular program (Myasthenia Gravis), brought in when under 20% of planned sites were available, Leapcure pre-screened 530+ patients, assigned 220 to sites, and delivered 8 of the final 10 enrollments. We never state or imply a CIDP-specific result we do not yet hold.

The Challenge

CIDP trial recruitment demands more than reach. It demands specialist access, disciplined pre-screening of complex eligibility, and the patient trust that only trusted communities carry.

The diagnosis is hard, so the enrollment is hard

CIDP is confirmed through nerve conduction studies and EMG, and patients are often misdiagnosed before reaching a specialist. Eligibility is complex and heterogeneous, and treatment histories across IVIG, corticosteroids, and plasma exchange have to be reconciled. Generic campaigns surface patients who fail screening and spend scarce specialist-site time on people the protocol cannot use.

Our medical-operations team carries NCS/EMG validation and treatment-history detail, so patients are pre-qualified and documentation-ready before any site referral.

Patients are reached through specialists, not list buys

Most people with CIDP are managed by community neurologists rather than academic sites, and the patient community is small and tight-knit. Cold digital and purchased lists do not reach them. Recruitment works when research reaches patients through the physicians and advocacy voices they already rely on.

In adjacent rare-disease programs, Leapcure mobilizes existing advocacy and patient networks within 2 days of program launch.

It is a rare, dispersed, immune-mediated neuropathy

CIDP prevalence is about 8.9 per 100,000, so the eligible pool in any one region is tiny. It sits in the same rare, immune-mediated, demyelinating neuro-immunology family as Myasthenia Gravis and NMOSD, the family Leapcure recruits for, where reaching enough eligible patients means reaching them globally.

Leapcure recruits across this family, with an adjacent Myasthenia Gravis rescue and qualitative NMOSD experience that prove the specialist-outreach and patient-support model CIDP needs.

Long, event-driven trials carry dropout risk

CIDP studies run long and are event-driven, so keeping enrolled patients engaged is as important as finding them. A recruiter who hands sites referral volume rather than prepared, supported patients leaves sites carrying the burden and the study exposed to attrition.

A dedicated Patient Success Team supports patients and families from first contact through enrollment, reducing site burden and screen fails in long trials.

How Leapcure recruits for CIDP and rare-neuropathy trials

We lead with physician and specialist outreach for eligibility-sensitive reach, use precision digital for volume, and run complex pre-screening and family support through a Patient Success Team, anchored by two trusted advocacy partners.

1

Reach patients through specialists and trusted communities

We lead with physician and specialist outreach, the community neurologists who actually see CIDP, and pair it with precision digital for volume. Advocacy is anchored by NORD and the Autoimmune Association, so research reaches patients through voices they already trust rather than cold lists.

2

Pre-qualify complex eligibility before site referral

Our medical-operations and Patient Success Team work the complex CIDP eligibility detail, NCS/EMG validation, IVIG and steroid scheduling, and treatment history, through real human conversations and an in-house clinical-eligibility review. Sites conduct official screening and receive patients who are eligible, prepared, and documentation-ready.

3

Support patients and families through long, event-driven trials

A dedicated Patient Success Team supports each patient and their family from first contact through enrollment, carrying the eligibility detail that otherwise lands on sites. In rare, dispersed populations and long trials, this continuity is what reduces dropout and keeps stalled studies moving.

Adjacent proof, shown as adjacent: a rare neuromuscular rescue where Leapcure delivered 8 of the final 10 enrollments

Challenge Context

Program

An adjacent Phase 2 rare neuromuscular program (Myasthenia Gravis), in the same rare, immune-mediated family as CIDP

Challenge

A stalled rare-disease study brought to Leapcure within four months of LPI, with under 20% of planned sites available.

Why it is relevant to CIDP

It proves the specialist outreach, complex pre-screening, and patient-support model CIDP needs. This is adjacent proof, never a CIDP-specific result.

Results & Metrics

Rescue Delivery (adjacent, Myasthenia Gravis, Phase 2)

Brought on within four months of LPI with under 20% of planned sites available, Leapcure delivered 8 of the final 10 enrollments.

Reach and Readiness (adjacent program)

530+ patients pre-screened and 220 assigned to sites, supporting 10 active sites, with existing rare-disease networks mobilizable within 2 days of program launch.

NMOSD experience (shown qualitatively)

We reached rare, serostatus-sensitive patients through physician and specialist outreach, used digital to drive volume, and our Patient Success Team carried the eligibility detail and family support that reduced site burden. This is the model CIDP needs.

Average enrollment contribution (adjacent portfolio)

About 70% average enrollment contribution across Phase 2 rare autoimmune and neuromuscular studies.

Four channels. Built for CIDP. Specialist reach first

CIDP is won on specialist reach, pre-screening, and trust, not ad volume. Leapcure leads with physician and specialist outreach, adds precision digital for volume, runs complex pre-screening through a Patient Success Team, and brings answer-engine visibility, with advocacy anchored by two confirmed partners.

Channel 1: Physician and specialist outreach

  • •We lead with the community neurologists and specialists who actually see CIDP, for eligibility-sensitive reach that cold digital cannot match.
  • •This is the same physician and specialist outreach model we used to reach rare, serostatus-sensitive patients in NMOSD.
  • •Advocacy is anchored by two confirmed partners, NORD and the Autoimmune Association, co-developed rather than purchased.

Channel 2: Precision digital for volume

  • •Precision digital campaigns are mapped to your eligibility criteria and geographies to bring volume on top of specialist reach.
  • •Digital brings volume; specialist outreach brings the eligibility-sensitive reach that finds qualified CIDP patients.
  • •Spend is rebalanced in real time based on site capacity and screening performance.

Channel 3: Patient Success and medical-operations pre-screening

  • •Real human conversations plus an in-house clinical-eligibility review handle complex CIDP detail: NCS/EMG validation, IVIG and steroid scheduling, and treatment history.
  • •Patients are pre-qualified and documentation-ready before any site referral, so sites get ready candidates, not work.
  • •A dedicated Patient Success Team supports patients and families through long, event-driven trials, reducing dropout and site burden.

Channel 4: AEO and AI-search visibility, defined honestly

  • •Patients increasingly ask ChatGPT, Perplexity, and Google's AI Overview which trials they may qualify for. We make your trial's information genuinely retrievable for those engines.
  • •The advantage is structure (crawlable, server-rendered prose and clear Q&A), authority (first-party data, dated stats, cited sources, a visible last-updated date), and presence in the advocacy and ClinicalTrials.gov sources AI engines actually cite.
  • •This is not schema tricks, markup, or content written for machines. We never promise AI visibility through markup.

Anchored by two confirmed advocacy partners

On this page we name only confirmed partners. Leapcure's partnerships are active and co-developed, not list purchases, and they reach CIDP patients through organizations they already trust.

National Organization for Rare Disorders (NORD)

Leading US rare-disease advocacy organization and a credibility anchor across the rare, immune-mediated neuropathy community.

Autoimmune Association

National autoimmune advocacy organization reaching the broader immune-mediated patient population that CIDP belongs to.

Living with CIDP? A clinical trial may be an option to explore.

If you are living with CIDP, or caring for someone who is, a clinical trial may offer access to investigational treatments alongside your existing care, never instead of it. We know CIDP is a rare, complex condition that is often hard to diagnose, and we will never pressure you. Leapcure's team answers your questions honestly, explains what a trial involves, and supports you and your family step by step.

See if a trial may be right for you
Leapcure kangaroo mascot

Leapcure is built for exactly this kind of trial: rare, immune-mediated, neuromuscular, hard to diagnose, and dependent on specialist reach and patient trust. We rescue rare-disease studies when they are behind, reach patients through the specialists who actually see them, and pre-qualify complex eligibility before your sites do. In an adjacent rare neuromuscular rescue (Myasthenia Gravis) we delivered 8 of the final 10 enrollments, and we can mobilize existing rare-disease networks within 2 days of program launch. That is the partner you want on a CIDP study that is at risk.

Talk to our CIDP team